Search

Your search keyword '"Rollier, Christine S."' showing total 14 results
Start Over Author "Rollier, Christine S." Database Supplemental Index
14 results on '"Rollier, Christine S."'

1. Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.

Author

Marsay, Leanne, Dold, Christina, Paterson, Gavin K., Yamaguchi, Yuko, Derrick, Jeremy P., Chan, Hannah, Feavers, Ian M., Maiden, Martin C.J., Wyllie, David, Hill, Adrian V., Pollard, Andrew J., and Rollier, Christine S.

Subjects
BACTERIAL proteins, ANIMAL experimentation, BACTERIAL antibodies, BACTERIAL antigens, OPIOID receptors, MENINGOCOCCAL vaccines, ANTIBODY formation, GRAM-negative aerobic bacteria, RESEARCH funding, BACTERIAL vaccines, MICE
Abstract

Objective: Adenoviral vectored vaccines, with the appropriate gene insert, induce cellular and antibody responses against viruses, parasites and intracellular pathogens such as Mycobacterium tuberculosis. Here we explored their capacity to induce functional antibody responses to meningococcal transmembrane outer membrane proteins.Methods: Vectors expressing porin A and ferric enterobactin receptor A antigens were generated, and their immunogenicity assessed in mice using binding and bactericidal assays.Results: The viral vectors expressed the bacterial proteins in an in vitro cell-infection assay and, after immunisation of mice, induced higher titres (>105 end-point titre) and longer lasting (>32 weeks) transgene-specific antibody responses in vivo than did outer membrane vesicles containing the same antigens. However, bactericidal antibodies, which are the primary surrogate of protection against meningococcus, were undetectable, despite different designs to support the presentation of the protective B-cell epitopes.Conclusion: These results demonstrate that, while the transmembrane bacterial proteins expressed by the viral vector induced strong and persistent antigen-specific antibodies, this platform failed to induce bactericidal antibodies. The results suggest that conformation or post-translational modifications of bacterial outer membrane antigens produced in eukaryote cells might not result in presentation of the necessary epitopes for induction of functional antibodies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

2. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Author

Barrett, Jordan R., Belij-Rammerstorfer, Sandra, Dold, Christina, Ewer, Katie J., Folegatti, Pedro M., Gilbride, Ciaran, Halkerston, Rachel, Hill, Jennifer, Jenkin, Daniel, Stockdale, Lisa, Verheul, Marije K., Aley, Parvinder K., Angus, Brian, Bellamy, Duncan, Berrie, Eleanor, Bibi, Sagida, Bittaye, Mustapha, Carroll, Miles W., Cavell, Breeze, Clutterbuck, Elizabeth A., Edwards, Nick, Flaxman, Amy, Fuskova, Michelle, Gorringe, Andrew, Hallis, Bassam, Kerridge, Simon, Lawrie, Alison M., Linder, Aline, Liu, Xinxue, Madhavan, Meera, Makinson, Rebecca, Mellors, Jack, Minassian, Angela, Moore, Maria, Mujadidi, Yama, Plested, Emma, Poulton, Ian, Ramasamy, Maheshi N., Robinson, Hannah, Rollier, Christine S., Song, Rinn, Snape, Matthew D., Tarrant, Richard, Taylor, Stephen, Thomas, Kelly M., Voysey, Merryn, Watson, Marion E. E., Wright, Daniel, Douglas, Alexander D., Green, Catherine M., Hill, Adrian V. S., Lambe, Teresa, Gilbert, Sarah, and Pollard, Andrew J.

Abstract

More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral spike protein may correlate with protection, additional antibody functions may also be important in preventing infection. Previously, we reported early immunogenicity and safety outcomes of a viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222), in a single-blinded phase 1/2 randomized controlled trial of healthy adults aged 18–55 years (NCT04324606). Now we describe safety and exploratory humoral and cellular immunogenicity of the vaccine, from subgroups of volunteers in that trial, who were subsequently allocated to receive a homologous full-dose (SD/SD D56; n= 20) or half-dose (SD/LD D56; n= 32) ChAdOx1 booster vaccine 56 d following prime vaccination. Previously reported immunogenicity data from the open-label 28-d interval prime-boost group (SD/SD D28; n= 10) are also presented to facilitate comparison. Additionally, we describe volunteers boosted with the comparator vaccine (MenACWY; n= 10). In this interim report, we demonstrate that a booster dose of ChAdOx1 nCoV-19 is safe and better tolerated than priming doses. Using a systems serology approach we also demonstrate that anti-spike neutralizing antibody titers, as well as Fc-mediated functional antibody responses, including antibody-dependent neutrophil/monocyte phagocytosis, complement activation and natural killer cell activation, are substantially enhanced by a booster dose of vaccine. A booster dose of vaccine induced stronger antibody responses than a dose-sparing half-dose boost, although the magnitude of T cell responses did not increase with either boost dose. These data support the two-dose vaccine regime that is now being evaluated in phase 3 clinical trials.

Published
2021
Full Text
View/download PDF

3. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Author

Ramasamy, Maheshi N, Minassian, Angela M, Ewer, Katie J, Flaxman, Amy L, Folegatti, Pedro M, Owens, Daniel R, Voysey, Merryn, Aley, Parvinder K, Angus, Brian, Babbage, Gavin, Belij-Rammerstorfer, Sandra, Berry, Lisa, Bibi, Sagida, Bittaye, Mustapha, Cathie, Katrina, Chappell, Harry, Charlton, Sue, Cicconi, Paola, Clutterbuck, Elizabeth A, Colin-Jones, Rachel, Dold, Christina, Emary, Katherine R W, Fedosyuk, Sofiya, Fuskova, Michelle, Gbesemete, Diane, Green, Catherine, Hallis, Bassam, Hou, Mimi M, Jenkin, Daniel, Joe, Carina C D, Kelly, Elizabeth J, Kerridge, Simon, Lawrie, Alison M, Lelliott, Alice, Lwin, May N, Makinson, Rebecca, Marchevsky, Natalie G, Mujadidi, Yama, Munro, Alasdair P S, Pacurar, Mihaela, Plested, Emma, Rand, Jade, Rawlinson, Thomas, Rhead, Sarah, Robinson, Hannah, Ritchie, Adam J, Ross-Russell, Amy L, Saich, Stephen, Singh, Nisha, Smith, Catherine C, Snape, Matthew D, Song, Rinn, Tarrant, Richard, Themistocleous, Yrene, Thomas, Kelly M, Villafana, Tonya L, Warren, Sarah C, Watson, Marion E E, Douglas, Alexander D, Hill, Adrian V S, Lambe, Teresa, Gilbert, Sarah C, Faust, Saul N, Pollard, Andrew J, Aboagye, Jeremy, Adams, Kelly, Ali, Aabidah, Allen, Elizabeth R., Allen, Lauren, Allison, Jennifer L., Andritsou, Foteini, Anslow, Rachel, Arbe-Barnes, Edward H., Baker, Megan, Baker, Natalie, Baker, Philip, Baleanu, Ioana, Barker, Debbie, Barnes, Eleanor, Barrett, Jordan R., Barrett, Kelly, Bates, Louise, Batten, Alexander, Beadon, Kirsten, Beckley, Rebecca, Bellamy, Duncan, Berg, Adam, Bermejo, Laura, Berrie, Eleanor, Beveridge, Amy, Bewley, Kevin, Bijker, Else M., Birch, Geeta, Blackwell, Luke, Bletchly, Heather, Blundell, Caitlin L., Blundell, Susannah R., Bolam, Emma, Boland, Elena, Bormans, Daan, Borthwick, Nicola, Boukas, Konstantinos, Bower, Thomas, Bowring, Francesca, Boyd, Amy, Brenner, Tanja, Brown, Phillip, Brown-O'Sullivan, Charlie, Bruce, Scott, Brunt, Emily, Burbage, Jamie, Burgoyne, Joshua, Buttigieg, Karen R., Byard, Nicholas, Cabera Puig, Ingrid, Camara, Susana, Cao, Michelangelo, Cappuccini, Federica, Carr, Melanie, Carroll, Miles W., Cashen, Paul, Cavey, Ana, Chadwick, Jim, Challis, Ruth, Chapman, David, Charles, David, Chelysheva, Irina, Cho, Jee-Sun, Cifuentes, Liliana, Clark, Elizabeth, Collins, Sarah, Conlon, Christopher P., Coombes, Naomi S., Cooper, Rachel, Cooper, Cushla, Crocker, Wendy E.M., Crosbie, Sarah, Cullen, Dan, Cunningham, Christina, Cuthbertson, Fiona, Datoo, Brad E., Dando, Lynne, Datoo, Mehreen S., Datta, Chandrabali, Davies, Hannah, Davies, Sarah, Davis, Elizabeth J., Davis, Judith, Dearlove, David, Demissie, Tesfaye, Di Marco, Stefania, Di Maso, Claudio, DiTirro, Danielle, Docksey, Claire, Dong, Tao, Donnellan, Francesca R., Douglas, Naomi, Downing, Charlotte, Drake, Jonathan, Drake-Brockman, Rachael, Drury, Ruth E., Dunachie, Susanna J., Edwards, Christopher J., Edwards, Nick J., El Muhanna, Omar, Elias, Sean C., Elliott, Ryan S., Elmore, Michael J., English, Marcus Rex, Felle, Sally, Feng, Shuo, Ferreira Da Silva, Carla, Field, Samantha, Fisher, Richard, Fixmer, Carine, Ford, Karen J., Fowler, Jamie, Francis, Emma, Frater, John, Furze, Julie, Galian-Rubio, Pablo, Galloway, Celine, Garlant, Harriet, Gavrila, Madita, Gibbons, Felicity, Gibbons, Karyna, Gilbride, Ciaran, Gill, Hardeep, Godwin, Kerry, Gordon-Quayle, Katherine, Gorini, Giacomo, Goulston, Lyndsey, Grabau, Caroline, Gracie, Lara, Graham, Nichola, Greenwood, Nicola, Griffiths, Oliver, Gupta, Gaurav, Hamilton, Elizabeth, Hanumunthadu, Brama, Harris, Stephanie A., Harris, Tara, Harrison, Daisy, Hart, Thomas C., Hartnell, Birgit, Haskell, Louise, Hawkins, Sophia, Henry, John Aaron, Hermosin Herrera, Macarena, Hill, David, Hill, Jennifer, Hodges, Gina, Hodgson, Susanne H.C., Horton, Katie L., Howe, Elizabeth, Howell, Nicola, Howes, Jessica, Huang, Ben, Humphreys, Jonathan, Humphries, Holly E., Iveson, Poppy, Jackson, Frederic, Jackson, Susan, Jauregui, Sam, Jeffers, Helen, Jones, Bryony, Jones, Christine E., Jones, Elizabeth, Jones, Kathryn, Joshi, Amar, Kailath, Reshma, Keen, Jade, Kelly, Dearbhla M., Kelly, Sarah, Kelly, Debbie, Kerr, David, Khan, Liaquat, Khozoee, Baktash, Killen, Annabel, Kinch, Jasmin, King, Lloyd D.W., King, Thomas B., Kingham, Lucy, Klenerman, Paul, Knight, Julian C., Knott, Daniel, Koleva, Stanislava, Lang, Gail, Larkworthy, Colin W., Larwood, Jessica P.J., Law, Rebecca, Lee, Arlene, Lee, Kim Y.N., Lees, Emily A., Leung, Stephanie, Li, Yuanyuan, Lias, Amelia M., Linder, Aline, Lipworth, Samuel, Liu, Shuchang, Liu, Xinxue, Lloyd, Stephanie, Loew, Lisa, Lopez Ramon, Raquel, Madhavan, Meera, Mainwaring, David O., Mallett, Garry, Mansatta, Kushal, Marinou, Spyridoula, Marius, Phedra, Marlow, Emma, Marriott, Paula, Marshall, Julia L., Martin, Jane, Masters, Shauna, McEwan, Joanne, McGlashan, Joanna L., McInroy, Lorna, McRobert, Nicky, Megson, Clare, Mentzer, Alexander J., Mirtorabi, Neginsadat, Mitton, Celia, Moore, Maria, Moran, Marni, Morey, Ella, Morgans, Róisín, Morris, Susan J., Morrison, Hazel Morrison, Morshead, Gertraud, Morter, Richard, Moya, Nathifa A., Mukhopadhyay, Ekta, Muller, Jilly, Munro, Claire, Murphy, Sarah, Mweu, Philomena, Noé, Andrés, Nugent, Fay L., O'Brien, Katie, O'Connor, Daniel, Oguti, Blanché, Olchawski, Victoria, Oliveira, Catarina, O'Reilly, Peter John, Osborne, Piper, Owen, Lydia, Owino, Nelly, Papageorgiou, Panagiotis, Parracho, Helena, Parsons, Karen, Patel, Bhumika, Patrick-Smith, Maia, Peng, Yanchun, Penn, Elizabeth J., Peralta-Alvarez, Marco Polo, Perring, James, Petropoulos, Christos, Phillips, Daniel J., Pipini, Dimitra, Pollard, Samuel, Poulton, Ian, Pratt, Danny, Presland, Laura, Proud, Pamela C., Provstgaard-Morys, Samuel, Pueschel, Sophie, Pulido, David, Rabara, Ria, Radia, Kajal, Rajapaska, Durga, Ramos Lopez, Fernando, Ratcliffe, Helen, Rayhan, Sara, Rees, Byron, Reyes Pabon, Emilia, Roberts, Hannah, Robertson, Isla, Roche, Sophie, Rollier, Christine S., Romani, Rossana, Rose, Zoe, Rudiansyah, Indra, Sabheha, Sabeha, Salvador, Stephannie, Sanders, Helen, Sanders, Katherine, Satti, Iman, Sayce, Chloe, Schmid, Annina B., Schofield, Ella, Screaton, Gavin, Sedik, Cynthia, Seddiqi, Samiullah, Segireddy, Rameswara R., Selby, Beatrice, Shaik, Imam, Sharpe, Hannah R., Shaw, Robert, Shea, Adam, Silk, Sarah, Silva-Reyes, Laura, Skelly, Donal T., Smith, David J., Smith, Daniel C., Smith, Nicholas, Spencer, Alexandra J., Spoors, Louise, Stafford, Elizabeth, Stamford, Imogen, Stockdale, Lisa, Stockley, David, Stockwell, Lisa V., Stokes, Matthew, Strickland, Louise H., Stuart, Arabella, Sulaiman, Sulaiman, Summerton, Eloise, Swash, Zoe, Szigeti, Anna, Tahiri-Alaoui, Abdessamad, Tanner, Rachel, Taylor, Iona, Taylor, Keja, Taylor, Ursula, te Water Naude, Rebecca, Themistocleous, Andreas, Thomas, Merin, Thomas, Tonia M., Thompson, Amber, Thompson, Kevin, Thornton-Jones, Viv, Tinh, Lan, Tomic, Adriana, Tonks, Susan, Towner, James, Tran, Nguyen, Tree, Julian A., Truby, Adam, Turner, Cheryl, Turner, Richard, Ulaszewska, Marta, Varughese, Rachel, Verbart, Dennis, Verheul, Marije K., Vichos, Iason, Walker, Laura, Wand, Matthew E., Watkins, Bridget, Welch, Jessica, West, Alison J., White, Caroline, White, Rachel, Williams, Paul, Woodyer, Mark, Worth, Andrew T., Wright, Daniel, Wrin, Terri, Yao, Xin Li, Zbarcea, Diana-Andreea, and Zizi, Dalila

Abstract

Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity of vaccines is often worse in older adults as a result of immunosenescence. We have reported the immunogenicity of a novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222), in young adults, and now describe the safety and immunogenicity of this vaccine in a wider range of participants, including adults aged 70 years and older.

Published
2020
Full Text
View/download PDF

4. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Author

Folegatti, Pedro M, Ewer, Katie J, Aley, Parvinder K, Angus, Brian, Becker, Stephan, Belij-Rammerstorfer, Sandra, Bellamy, Duncan, Bibi, Sagida, Bittaye, Mustapha, Clutterbuck, Elizabeth A, Dold, Christina, Faust, Saul N, Finn, Adam, Flaxman, Amy L, Hallis, Bassam, Heath, Paul, Jenkin, Daniel, Lazarus, Rajeka, Makinson, Rebecca, Minassian, Angela M, Pollock, Katrina M, Ramasamy, Maheshi, Robinson, Hannah, Snape, Matthew, Tarrant, Richard, Voysey, Merryn, Green, Catherine, Douglas, Alexander D, Hill, Adrian V S, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J, Aboagye, Jeremy, Adams, Kelly, Ali, Aabidah, Allen, Elizabeth, Allison, Jennifer L., Anslow, Rachel, Arbe-Barnes, Edward H., Babbage, Gavin, Baillie, Kenneth, Baker, Megan, Baker, Natalie, Baker, Philip, Baleanu, Ioana, Ballaminut, Juliana, Barnes, Eleanor, Barrett, Jordan, Bates, Louise, Batten, Alexander, Beadon, Kirsten, Beckley, Rebecca, Berrie, Eleanor, Berry, Lisa, Beveridge, Amy, Bewley, Kevin R., Bijker, Else Margreet, Bingham, Tracey, Blackwell, Luke, Blundell, Caitlin L., Bolam, Emma, Boland, Elena, Borthwick, Nicola, Bower, Thomas, Boyd, Amy, Brenner, Tanja, Bright, Philip D., Brown-O'Sullivan, Charlie, Brunt, Emily, Burbage, Jamie, Burge, Sharon, Buttigieg, Karen R., Byard, Nicholas, Cabera Puig, Ingrid, Calvert, Anna, Camara, Susana, Cao, Michelangelo, Cappuccini, Federica, Carr, Melanie, Carroll, Miles W., Carter, Victoria, Cathie, Katrina, Challis, Ruth J., Charlton, Sue, Chelysheva, Irina, Cho, Jee-Sun, Cicconi, Paola, Cifuentes, Liliana, Clark, Helen, Clark, Elizabeth, Cole, Tom, Colin-Jones, Rachel, Conlon, Christopher P., Cook, Aislinn, Coombes, Naomi S., Cooper, Rachel, Cosgrove, Catherine A., Coy, Karen, Crocker, Wendy E.M., Cunningham, Christina J., Damratoski, Brad E., Dando, Lynne, Datoo, Mehreen S., Davies, Hannah, De Graaf, Hans, Demissie, Tesfaye, Di Maso, Claudio, Dietrich, Isabelle, Dong, Tao, Donnellan, Francesca R., Douglas, Naomi, Downing, Charlotte, Drake, Jonathan, Drake-Brockman, Rachael, Drury, Ruth Elizabeth, Dunachie, Susanna Jane, Edwards, Nick J., Edwards, Frances D.L., Edwards, Chris J., Elias, Sean C., Elmore, Michael J., Emary, Katherine R.W., English, Marcus Rex, Fagerbrink, Susanne, Felle, Sally, Feng, Shuo, Field, Samantha, Fixmer, Carine, Fletcher, Clare, Ford, Karen J., Fowler, Jamie, Fox, Polly, Francis, Emma, Frater, John, Furze, Julie, Fuskova, Michelle, Galiza, Eva, Gbesemete, Diane, Gilbride, Ciaran, Godwin, Kerry, Gorini, Giacomo, Goulston, Lyndsey, Grabau, Caroline, Gracie, Lara, Gray, Zoe, Guthrie, Lucy Belle, Hackett, Mark, Halwe, Sandro, Hamilton, Elizabeth, Hamlyn, Joseph, Hanumunthadu, Brama, Harding, Irasha, Harris, Stephanie A., Harris, Andrew, Harrison, Daisy, Harrison, Clare, Hart, Thomas C., Haskell, Louise, Hawkins, Sophia, Head, Ian, Henry, John Aaron, Hill, Jennifer, Hodgson, Susanne H.C., Hou, Mimi M., Howe, Elizabeth, Howell, Nicola, Hutlin, Cecilia, Ikram, Sabina, Isitt, Catherine, Iveson, Poppy, Jackson, Susan, Jackson, Frederic, James, Sir William, Jenkins, Megan, Jones, Elizabeth, Jones, Kathryn, Jones, Christine E., Jones, Bryony, Kailath, Reshma, Karampatsas, Konstantinos, Keen, Jade, Kelly, Sarah, Kelly, Dearbhla, Kerr, David, Kerridge, Simon, Khan, Liaquat, Khan, Uzma, Killen, Annabel, Kinch, Jasmin, King, Thomas B., King, Lloyd, King, Jade, Kingham-Page, Lucy, Klenerman, Paul, Knapper, Francesca, Knight, Julian C., Knott, Daniel, Koleva, Stanislava, Kupke, Alexandra, Larkworthy, Colin W., Larwood, Jessica P.J., Laskey, Anna, Lawrie, Alison M., Lee, Arlene, Ngan Lee, Kim Yee, Lees, Emily A, Legge, Helen, Lelliott, Alice, Lemm, Nana-Marie, Lias, Amelia M., Linder, Aline, Lipworth, Samuel, Liu, Xinxue, Liu, Shuchang, Lopez Ramon, Raquel, Lwin, May, Mabesa, Francesca, Madhavan, Meera, Mallett, Garry, Mansatta, Kushal, Marcal, Ines, Marinou, Spyridoula, Marlow, Emma, Marshall, Julia L., Martin, Jane, McEwan, Joanne, McInroy, Lorna, Meddaugh, Gretchen, Mentzer, Alexander J., Mirtorabi, Neginsadat, Moore, Maria, Moran, Edward, Morey, Ella, Morgan, Victoria, Morris, Susan Jane, Morrison, Hazel, Morshead, Gertraud, Morter, Richard, Mujadidi, Yama F., Muller, Jilly, Munera-Huertas, Tatiana, Munro, Claire, Munro, Alasdair, Murphy, Sarah, Munster, Vincent J., Mweu, Philomena, Noé, Andrés, Nugent, Fay L., Nuthall, Elizabeth, O'Brien, Katie, O'Connor, Daniel, Oguti, Blanché, Oliver, Jennifer L., Oliveira, Catarina, O'Reilly, Peter John, Osborn, Mairead, Osborne, Piper, Owen, Cathy, Owens, Daniel, Owino, Nelly, Pacurar, Mihaela, Parker, Kaye, Parracho, Helena, Patrick-Smith, Maia, Payne, Victoria, Pearce, Jennifer, Peng, Yanchun, Peralta Alvarez, Marco Polo, Perring, James, Pfafferott, Katja, Pipini, Dimitra, Plested, Emma, Pluess-Hall, Helen, Pollock, Katrina, Poulton, Ian, Presland, Laura, Provstgaard-Morys, Samuel, Pulido, David, Radia, Kajal, Ramos Lopez, Fernando, Rand, Jade, Ratcliffe, Helen, Rawlinson, Thomas, Rhead, Sarah, Riddell, Amy, Ritchie, Adam John, Roberts, Hannah, Robson, Joanna, Roche, Sophie, Rohde, Cornelius, Rollier, Christine S., Romani, Rossana, Rudiansyah, Indra, Saich, Stephen, Sajjad, Sara, Salvador, Stephannie, Sanchez Riera, Lidia, Sanders, Helen, Sanders, Katherine, Sapaun, Shari, Sayce, Chloe, Schofield, Ella, Screaton, Gavin, Selby, Beatrice, Semple, Calum, Sharpe, Hannah R., Shaik, Imam, Shea, Adam, Shelton, Holly, Silk, Sarah, Silva-Reyes, Laura, Skelly, Donal T., Smee, Heather, Smith, Catherine C., Smith, David J., Song, Rinn, Spencer, Alexandra J., Stafford, Elizabeth, Steele, Amy, Stefanova, Elena, Stockdale, Lisa, Szigeti, Anna, Tahiri-Alaoui, Abdessamad, Tait, Moira, Talbot, Helen, Tanner, Rachel, Taylor, Iona Jennifer, Taylor, Victoria, Te Water Naude, Rebecca, Thakur, Nazia, Themistocleous, Yrene, Themistocleous, Andreas, Thomas, Merin, Thomas, Tonia M., Thompson, Amber, Thomson-Hill, Samantha, Tomlins, Jennifer, Tonks, Susan, Towner, James, Tran, Nguyen, Tree, Julia A., Truby, Adam, Turkentine, Kate, Turner, Cheryl, Turner, Nicola, Turner, Sally, Tuthill, Toby, Ulaszewska, Marta, Varughese, Rachel, Van Doremalen, Neeltje, Veighey, Kristin, Verheul, Marije K., Vichos, Iason, Vitale, Elia, Walker, Laura, Watson, Marion E.E., Welham, Benjamin, Wheat, Julie, White, Caroline, White, Rachel, Worth, Andrew T., Wright, Danny, Wright, Suzie, Yao, Xin Li, and Yau, Yasmine

Abstract

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.

Published
2020
Full Text
View/download PDF

5. Rapid travel to a Zika vaccine: are we heading towards success or more questions?

Author

Britto, Carl, Dold, Christina, Reyes-Sandoval, Arturo, and Rollier, Christine S.

Abstract

ABSTRACTIntroduction: The emergence of the Zika virus (ZIKV) in Latin America in 2015–2016 led to an expeditious search for vaccine candidates, with a DNA-based candidate having progressed to Phase II. However, several features of ZIKV infection and epidemiology are not understood, which may be key to maximizing efficacy and ensuring safety of ZIKV vaccines.Areas covered: Conceivable problems related to vaccine development and policy include: (1) paucity of diagnostics to satisfactorily discriminate between past ZIKV and dengue virus (DENV) exposure; (2) insufficient knowledge of the mechanisms of ZIKV neurovirulence, amongst other unknowns in the biology of this infection, is particularly relevant from a vaccine safety perspective; and (3) the potential for disease enhancement, as observed with DENV infection and vaccine.Expert opinion: Vaccine candidates that entered phase I/II trials have demonstrated protection in naïve animal models, while ZIKV epidemics occurred in populations that had encountered DENV before. The resulting cross-reactive antibodies pose problems for reliable serologic diagnostic assays, and for the potential of disease enhancement. The alleged neurological complications also warrant further exploration in order to reassure regulators of the safety profile of these vaccines in target populations. These research aspects should be an integral part of the efforts to develop a vaccine.

Published
2018
Full Text
View/download PDF

6. An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease

Author

Dold, Christina, Marsay, Leanne, Wang, Nelson, Silva-Reyes, Laura, Clutterbuck, Elizabeth, Paterson, Gavin K., Sharkey, Kelsey, Wyllie, David, Beernink, Peter T., Hill, Adrian V., Pollard, Andrew J., and Rollier, Christine S.

Abstract

Adenoviral-vectored vaccines are licensed for prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ebola virus, but, for bacterial proteins, expression in a eukaryotic cell may affect the antigen’s localization and conformation or lead to unwanted glycosylation. Here, we investigated the potential use of an adenoviral-vectored vaccine platform for capsular group B meningococcus (MenB). Vector-based candidate vaccines expressing MenB antigen factor H binding protein (fHbp) were generated, and immunogenicity was assessed in mouse models, including the functional antibody response by serum bactericidal assay (SBA) using human complement. All adenovirus-based vaccine candidates induced high antigen-specific antibody and T cell responses. A single dose induced functional serum bactericidal responses with titers superior or equal to those induced by two doses of protein-based comparators, as well as longer persistence and a similar breadth. The fHbp transgene was further optimized for human use by incorporating a mutation abrogating binding to the human complement inhibitor factor H. The resulting vaccine candidate induced high and persistent SBA responses in transgenic mice expressing human factor H. The optimized transgene was inserted into the clinically relevant ChAdOx1 backbone, and this vaccine has now progressed to clinical development. The results of this preclinical vaccine development study underline the potential of vaccines based on genetic material to induce functional antibody responses against bacterial outer membrane proteins.

Published
2023
Full Text
View/download PDF

7. Needle-Free Dermal Delivery of a Diphtheria Toxin CRM197Mutant on Potassium-Doped Hydroxyapatite Microparticles

Author

Weissmueller, Nikolas T., Schiffter, Heiko A., Carlisle, Robert C., Rollier, Christine S., and Pollard, Andrew J.

Abstract

ABSTRACTInjections with a hypodermic needle and syringe (HNS) are the current standard of care globally, but the use of needles is not without limitation. While a plethora of needle-free injection devices exist, vaccine reformulation is costly and presents a barrier to their widespread clinical application. To provide a simple, needle-free, and broad-spectrum protein antigen delivery platform, we developed novel potassium-doped hydroxyapatite (K-Hap) microparticles with improved protein loading capabilities that can provide sustained local antigen presentation and release. K-Hap showed increased protein adsorption over regular hydroxyapatite (P< 0.001), good structural retention of the model antigen (CRM197) with 1% decrease in a-helix content and no change in ß-sheet content upon adsorption, and sustained release in vitro. Needle-free intradermal powder inoculation with K-Hap–CRM197induced significantly higher IgG1 geometric mean titers (GMTs) than IgG2a GMTs in a BALB/c mouse model (P< 0.001) and induced IgG titer levels that were not different from the current clinical standard (P> 0.05), namely, alum-adsorbed CRM197by intramuscular (i.m.) delivery. The presented results suggest that K-Hap microparticles may be used as a novel needle-free delivery vehicle for some protein antigens.

Published
2015
Full Text
View/download PDF

8. The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy

Author

Rollier, Christine S, Dold, Christina, Marsay, Leanne, Sadarangani, Manish, and Pollard, Andrew J

Abstract

Introduction:Capsular group B meningococcal disease is a leading cause of childhood meningitis and septicaemia. Up to 10% of sufferers die, and sequelae remain in > 30% of survivors. A vaccine, four component meningococcal group B (4CMenB), designed with the aim to induce broad coverage against this highly variable bacterium, has been licensed in countries including in the European Union, Canada and Australia.Areas covered:Immunogenicity and safety data, published in peer-reviewed literature between 2004 and 2014, are presented in the context of the recent recommendation for the use of the vaccine in infants in the UK.Expert opinion:4CMenB induces significant reactogenicity when administered with routine infant vaccines, in particular with respect to fever rates. Fevers can be somewhat reduced using paracetamol. The efficacy of the vaccine is unknown but has been extrapolated from effectiveness data obtained from use of one of its components in New Zealand, immunogenicity data from clinical trials and estimation of coverage from in vitrostudies. These data suggest that the vaccine will prevent a proportion of invasive meningococcal disease cases in infants and young children. Implementation and well-planned post-marketing surveillance will address uncertainties over field effectiveness.

Published
2015
Full Text
View/download PDF

9. Neisseria meningitidisNative Outer Membrane Vesicles Containing Different Lipopolysaccharide Glycoforms as Adjuvants for Meningococcal and Nonmeningococcal Antigens

Author

Nagaputra, Jerry C., Rollier, Christine S., Sadarangani, Manish, Hoe, J. Claire, Mehta, Ojas Hrakesh, Norheim, Gunnstein, Saleem, Muhammad, Chan, Hannah, Derrick, Jeremy P., Feavers, Ian, Pollard, Andrew J., and Moxon, E. Richard

Abstract

ABSTRACTWe evaluated the adjuvant effect of a modified glycoform of lipopolysaccharide (LPS) (LgtB-LpxL1) compared to that of the nonmodified glycoform Lpxl1 serogroup B meningococcal H44/76 native outer membrane vesicles (nOMVs) on immune responses to vaccination with the recombinant meningococcal protein, rPorA, tetanus toxoid, or meningococcal serogroup C capsular polysaccharide. We used LgtB-LpxL1 LPS because the disruption of the lgtBgene, which results in the exposure of N-acetylglucosamine-galactose-glucose residues in the LPS outer core, has been shown to enhance the activation of human dendritic cells in vitro. The responses were compared to those of a monophosphoryl lipid A (MPL)-based adjuvant and to an aluminum hydroxide suspension. The nOMVs induced blood serum IgG responses against each of the three antigens comparable to those obtained with MPL or aluminum salt. However, nOMVs elicited (i) a lower IgG1/IgG2a ratio against rPorA and (ii) serum bactericidal antibody titers superior to those achieved with aluminum salt, reaching similar titers to those obtained with MPL. Similarly, bactericidal antibody titers induced by immunization with meningococcal serogroup C polysaccharide and nOMVs were similar to those obtained using MPL but were better than those with aluminum salt. Immunization with tetanus toxoid and nOMVs resulted in tetanus toxoid-specific IgG responses similar to those obtained when adjuvanted with aluminum salt. These results highlight the potential utility of meningococcal LpxL1 LPS-containing nOMVs as an adjuvant for recombinant meningococcal protein vaccines and suggest their possible use with a variety of other antigens.

Published
2013
Full Text
View/download PDF

10. Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines

Author

Montalvo Zurbia-Flores, Gerardo, Rollier, Christine S, and Reyes-Sandoval, Arturo

Abstract

ABSTRACTDespite the existence of a highly efficient yellow fever vaccine, yellow fever reemergence throughout Africa and the Americas has put 900 million people in 47 countries at risk of contracting the disease. Although the vaccine has been key to controlling yellow fever epidemics, its live-attenuated nature comes with a range of contraindications that prompts advising against its administration to pregnant and lactating women, immunocompromised individuals, and those with hypersensitivity to chicken egg proteins. Additionally, large outbreaks have highlighted problems with insufficient vaccine supply, whereby manufacturers rely on slow traditional manufacturing processes that prevent them from ramping up production. These limitations have contributed to an inadequate control of yellow fever and have favored the pursuit of novel yellow fever vaccine candidates that aim to circumvent the licensed vaccine’s restrictions. Here, we review the live-attenuated vaccine’s limitations and explore the epitome of a yellow fever vaccine, whilst scrutinizing next-generation vaccine candidates.

Published
2022
Full Text
View/download PDF

11. Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Author

Barrett, Jordan R., Belij-Rammerstorfer, Sandra, Dold, Christina, Ewer, Katie J., Folegatti, Pedro M., Gilbride, Ciaran, Halkerston, Rachel, Hill, Jennifer, Jenkin, Daniel, Stockdale, Lisa, Verheul, Marije K., Aley, Parvinder K., Angus, Brian, Bellamy, Duncan, Berrie, Eleanor, Bibi, Sagida, Bittaye, Mustapha, Carroll, Miles W., Cavell, Breeze, Clutterbuck, Elizabeth A., Edwards, Nick, Flaxman, Amy, Fuskova, Michelle, Gorringe, Andrew, Hallis, Bassam, Kerridge, Simon, Lawrie, Alison M., Linder, Aline, Liu, Xinxue, Madhavan, Meera, Makinson, Rebecca, Mellors, Jack, Minassian, Angela, Moore, Maria, Mujadidi, Yama, Plested, Emma, Poulton, Ian, Ramasamy, Maheshi N., Robinson, Hannah, Rollier, Christine S., Song, Rinn, Snape, Matthew D., Tarrant, Richard, Taylor, Stephen, Thomas, Kelly M., Voysey, Merryn, Watson, Marion E. E., Wright, Daniel, Douglas, Alexander D., Green, Catherine M., Hill, Adrian V. S., Lambe, Teresa, Gilbert, Sarah, and Pollard, Andrew J.

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41591-021-01372-z.

Published
2021
Full Text
View/download PDF

13. Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci

Author

Giuntini, Serena, Lujan, Eduardo, Gibani, Malick M., Dold, Christina, Rollier, Christine S., Pollard, Andrew J., and Granoff, Dan M.

Abstract

ABSTRACTMenB-4C is a meningococcal vaccine for the prevention of serogroup B disease. The vaccine contains factor H binding protein (FHbp) and three other antigens that can elicit serum bactericidal antibodies (SBA). For vaccine licensure, efficacy was inferred from the SBA responses against three antigen-specific indicator strains. The relation between those results and broad protection against circulating genetically diverse strains is not known. Twenty adults were immunized with two doses of MenB-4C given 1 to 2 months apart. SBA activity against 3 reference strains and 15 serogroup B test strains (6 from college outbreaks) was measured. Compared to the preimmunization titers, 70%, 95%, and 95% of subjects had =4-fold increases in the titers of anti-PorA P1.4, anti-NadA, and anti-FHbp antibodies against the reference strains, respectively. In contrast, only 25 to 45% of the subjects had =4-fold increases in responses to 10 of the 15 test strains, including 8 that expressed one to three of the antigens in the vaccine. At 1 month, the majority of subjects with <4-fold titer increases had serum titers of =1:4, which are considered sufficient for protection. However, the titers against four strains declined to <1:4 by 4 to 6 months in one-third to greater than 50% of the subjects tested. Clinically relevant isolates are often more resistant to SBA than the indicator strains used to measure antigen-specific SBA. A working model is that the percentage of subjects with titers of =1:4 at 1 month postimmunization correlates with short-term protection against that strain, whereas the percentage of subjects with =4-fold titer increases represents a more robust response. (The protocol used at the Oxford Vaccine Group has been registered at ClinicalTrials.gov under registration no. NCT02398396.)

Published
2016
Full Text
View/download PDF

14. Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass

Author

Alcock, Robert, Cottingham, Matthew G., Rollier, Christine S., Furze, Julie, De Costa, Samodh D., Hanlon, Marian, Spencer, Alexandra J., Honeycutt, Jared D., Wyllie, David H., Gilbert, Sarah C., Bregu, Migena, and Hill, Adrian V. S.

Abstract

A sucrose-trehalose glass film dried onto a filter can preserve the activity of two potential live viral vaccine vectors at elevated temperatures for up to 6 months.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results